Direct-acting Antiviral Drugs Market
Direct-acting Antiviral Drugs Market Scope: Industry
Analysis, Market Size, Growth, Trends Till 2031
Request Sample Report
Direct-acting Antiviral Drugs Market Size and Growth
The Direct-acting Antiviral Drugs market is experiencing significant growth, driven by rising global hepatitis and HIV prevalence and increased healthcare investments. The market was valued at approximately $25 billion in 2023, with a projected CAGR of 7% from 2024 to 2030, reflecting heightened demand for advanced antiviral therapies and innovative drug developments.
Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ AbbVie Inc.
◍ GSK
◍ Boehringer Ingelheim
◍ Merck
◍ Novartis
◍ Beximco Pharmaceuticals
◍ Roche
◍ Bristol-Myers Squibb Company
◍ Gilead Sciences
◍ Janssen (Johnson & Johnson)
◍ Vertex Pharmaceuticals
◍ Natco Pharma
The Direct-acting Antiviral Drugs Market features major players like AbbVie, GSK, Boehringer Ingelheim, and Gilead Sciences, focusing on innovative therapies for viral infections. Their investments in R&D and extensive product portfolios drive market growth. Notable revenue includes Gilead's $6.3 billion in 2022 from antiviral sales.
Request Sample Report
Market Segmentation
By Application By Product
◍ Hospitals
◍ Clinics
◍ Ambulatory Surgical Centers
◍ Pharmacies
◍ Others
◍ NS3/4A Protease Inhibitors
◍ Nucleoside and Nucleotide NS5B Polymerase Inhibitors
◍ NS5A Inhibitors
◍ Non-Nucleoside NS5B Polymerase Inhibitors
Request Sample Report
Market Growth
Request Sample Report
$ X Billion USD
